Intravenous Lidocaine Infusion Versus Intravenous Dexmedetomidine Infusion During Sleeve Gastrectomy
Trial Parameters
Brief Summary
Although laparoscopic (LAP) bariatric surgery is minimally invasive. Following any laparoscopic procedure, patients typically experience the peak of postoperative pain within the first 24 hours. This intense pain gradually subsides, with significant relief usually occurring by the 2nd or 3rd postoperative day. The initial peak and subsequent decline in pain intensity highlight the importance of effective early pain management strategies to ensure patient comfort and recovery during this critical period. Inadequate management of postoperative pain can result in serious complications. Lidocaine is increasingly recognised as a vital adjunct in managing perioperative pain. Its efficacy extends beyond traditional local anaesthetic applications, as it also demonstrates analgesic, anti-hyperalgesic, and anti-inflammatory properties. Dexmedetomidine is a highly selective alpha-2 adrenergic agonist with hypnotic, sedative, anxiolytic, sympatholytic, and analgesic effects, while causing minimal respiratory depression
Eligibility Criteria
Inclusion Criteria: * Age: 20-50 years, both sexes. * American Standards Association (ASA) physical status class II to III. * Body mass index (BMI) 35-50 kg m-². Exclusion Criteria: * Cardiac conduction disorders. * Cardiomyopathy. * Chronic opioid use. * Allergy to the studied medications. * Pregnancy and breastfeeding.